About Us Volumetric is a recognized world leader in building living multicellular tissues, with a focus on replicating discrete functions of the human body for basic mechanistic biology, laboratory testing and screening, and drug development. Founded in 2018 by Bagrat Grigoryan and Jordan Miller as a spin-out from Rice University, the full potential of our work is to build whole human organ replacements for patients, made from their own cells.
Volumetric is a Y Combinator company in the Winter 2020 batch. Its directory entry describes it as: Volumetric builds living multicellular tissues with a focus on the…. The founders listed are Jordan Miller (Founder/President), Bagrat Grigoryan (Founder/COO) (Y Combinator directory entry, June 11, 2020).
Sell to companies like Volumetric? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2020-06-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Volumetric.
Free to see. No signup.
More on Volumetric and the records around it.
Same batch, Healthcare first.
Get an email when Volumetric changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Volumetric raises, hires or launches. No email unless you switch it on.
Watch Volumetric →Get the full cited report on Volumetric
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Volumetric: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
About Us Volumetric is a recognized world leader in building living multicellular tissues, with a focus on replicating discrete functions of the human body for basic mechanistic biology, laboratory testing and screening, and drug development. Founded in 2018 by Bagrat Grigoryan and Jordan Miller as a spin-out from Rice University, the full potential of our work is to build whole human organ replacements for patients, made from their own cells. Our Technology and Approach We have invented a suite of breakthrough 3D bioprinting technologies, featured on the cover of Science, that can build human tissue with complex blood vessel networks. We are leveraging this technology in the short term to build patient-specific tissues for drug safety and efficacy testing. Patient cells are taken from a biopsy, added to our proprietary 3D printed tissues, and then drug compounds are injected through the blood vessel network to mimic actual drug delivery in humans. Our vision is that our technology will provide rigorous, reproducible, and predictive outcomes for patients, resulting in drastically improved outcomes for diseases like cancer. More broadly, we see the full potential of our mission as being able to produce functional tissue and organ replacements for diseased or damaged vital organs in the body such as the lung, liver, pancreas, kidney, and heart.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Volumetric: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Volumetric covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist VolumetricYou get an alert in MentionFox the next time this company shows up.
If you're behind Volumetric: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Volumetric. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-volumetric